HilleVax (NASDAQ:HLVX) (NASDAQ: HLVX) is a clinical‐stage immunology company dedicated to developing next‐generation oral vaccines against gastrointestinal viruses. Leveraging a proprietary virus‐like particle (VLP) platform, the company’s lead candidate, HIL‐214, is a multivalent norovirus vaccine designed to induce broad and durable immune responses following a single oral dose. HilleVax’s pipeline further includes combination formulations targeting both norovirus and rotavirus, with the goal of addressing major causes of acute gastroenteritis in children and adults worldwide.
Founded in 2021, HilleVax operates out of its headquarters in Seattle, Washington, with research and manufacturing partnerships across North America, Europe and Asia. The company’s technology builds on decades of academic research into VLP immunogenicity and stability, enabling HilleVax to produce highly immunogenic oral formulations that can be deployed in resource‐limited settings without the need for strict cold‐chain management. Preclinical studies have demonstrated robust mucosal and systemic immune responses in multiple animal models, supporting the progression of HIL‐214 into Phase 1 clinical trials.
Under the leadership of co‐founder and Chief Executive Officer Michael Gross, Ph.D., a veteran of vaccine development with more than 25 years of experience in infectious diseases, and co‐founder and Chief Scientific Officer John Klippel, Ph.D., an expert in viral immunology, HilleVax has assembled a multidisciplinary team of virologists, immunologists and process engineers. The company collaborates with public‐private partnerships, global health organizations and contract development and manufacturing organizations (CDMOs) to accelerate clinical development and ensure scalable production capacity.
With a commitment to improving global health, HilleVax’s strategy focuses on advancing its oral vaccine candidates through clinical milestones while forging alliances in low‐ and middle‐income countries. By targeting both endemic and epidemic strains of gastroenteritis viruses, the company aims to deliver affordable, easy‐to‐administer vaccines that can reduce hospitalizations, curb outbreaks and support immunization programs in diverse geographic regions.
